Trametinib

Generic Name
Trametinib
Brand Names
Mekinist, Spexotras
Drug Type
Small Molecule
Chemical Formula
C26H23FIN5O4
CAS Number
871700-17-3
Unique Ingredient Identifier
33E86K87QN
Background

Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...

Indication

Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

It is used in combination with dabrafenib for the:
...

Associated Conditions
Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
Associated Therapies
-
Clinical Trials
Related News

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

First Posted Date
2018-10-22
Last Posted Date
2023-09-13
Lead Sponsor
Centre Leon Berard
Target Recruit Count
12
Registration Number
NCT03714958
Locations
🇫🇷

Centre Leon Berard, Lyon, France

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

First Posted Date
2018-09-12
Last Posted Date
2022-06-27
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
25
Registration Number
NCT03668431
Locations
🇺🇸

Dana Farber Cancer Institite, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hosital Cancer Center, Boston, Massachusetts, United States

Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas

First Posted Date
2018-08-15
Last Posted Date
2024-08-06
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Target Recruit Count
25
Registration Number
NCT03631953
Locations
🇫🇷

Assistance Publique Hôpitaux de Marseille, Marseille, France

Melanoma Metastasized to the Brain and Steroids

First Posted Date
2018-06-20
Last Posted Date
2023-07-13
Lead Sponsor
Inge Marie Svane
Target Recruit Count
80
Registration Number
NCT03563729
Locations
🇩🇰

Herlev Universityhospital, Herlev, Hovedstaden, Denmark

🇩🇰

Aarhus Universityhospital, Aarhus, Midt, Denmark

🇩🇰

Odense Universityhospital, Odense, Syd, Denmark

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Phase 3
Completed
Conditions
Malignant Melanoma
Interventions
Drug: Dabrafenib
Drug: Trametinib
First Posted Date
2018-06-11
Last Posted Date
2024-06-12
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
552
Registration Number
NCT03551626
Locations
🇬🇧

Novartis Investigative Site, Southampton, United Kingdom

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Phase 1
Completed
Conditions
Bronchial Neoplasms
Interventions
Drug: EGF816
Drug: Trametinib
First Posted Date
2018-05-04
Last Posted Date
2024-02-15
Lead Sponsor
University of Cologne
Target Recruit Count
18
Registration Number
NCT03516214
Locations
🇩🇪

University Hospital Dresden, Dresden, Germany

🇩🇪

University Hospital of Cologne, Cologne, Germany

🇪🇸

Vall d'Hebron University Hospital, Barcelona, Spain

and more 4 locations

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Phase 1
Active, not recruiting
Conditions
Melanoma
Unresectable Melanoma
Advanced Melanoma
Interventions
Drug: Ceritinib
Drug: Trametinib
First Posted Date
2018-04-18
Last Posted Date
2024-12-04
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
27
Registration Number
NCT03501368
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1
Completed
Conditions
Melanoma
Interventions
Drug: MCS110
Drug: Dabrafenib
Drug: Trametinib
First Posted Date
2018-03-07
Last Posted Date
2024-07-31
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
6
Registration Number
NCT03455764
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

First Posted Date
2018-02-15
Last Posted Date
2024-05-31
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
68
Registration Number
NCT03434262
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

First Posted Date
2018-02-09
Last Posted Date
2023-06-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
29
Registration Number
NCT03428126
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy